The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

开始日期2024-10-10

申办/合作机构

Eli Lilly & Co.

NCT06169982

/ Completed临床1期

A Phase 1, Open-Label, Multiple-Dose Study to Investigate Steady-State Pharmacokinetics and Pharmacodynamics During a Euglycemic Clamp of LY3209590 in Participants With Type 2 Diabetes Mellitus

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.

开始日期2023-12-07

申办/合作机构

Eli Lilly & Co.

NCT05914688

/ Completed临床1期

A Bioequivalence Study of Subcutaneous Injections of LY3209590 in Two Formulations in Healthy Participants

The main purpose of this study is to compare the two formulations of LY3209590 in healthy participants. Study participants will be administered each formulation at separate study visits. Blood samples will be taken to compare how the body handles study drugs. The information about any adverse effects experienced will be collected and the tolerability of LY3209590 will also be evaluated.
Screening is required within 28 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 184 days including screening.

开始日期2023-06-26

申办/合作机构

Eli Lilly & Co.

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的临床结果

登录后查看更多信息

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的转化医学

登录后查看更多信息

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的专利（医药）

登录后查看更多信息

115

项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的文献（医药）

2025-10-01·JOURNAL OF DIABETES AND ITS COMPLICATIONS

Degludec insulin versus efsitora insulin in diabetes mellitus management: A systematic review and meta-analysis

Article

作者: Gallo Ruelas, Mariano ; Flávio-Reis, Victor Hugo Palhares ; Queiroz, Ivo ; Barbosa, Lucas Mendes ; de Oliveira, Helen Michaela ; Zamora, Fernanda Valeriano ; Cavalcante, Deivyd Vieira Silva

PURPOSE:

To compare the efficacy and safety of next-generation basal insulin efsitora versus insulin degludec in managing type 1 and type 2 diabetes.

METHODS:

We systematically searched PubMed, Embase, and CENTRAL databases until October 2024. This study followed PRISMA guidelines. Statistical analyses were performed using R version 4.4.1. The risk of bias was assessed using the RoB2 tool, and the quality of evidence was evaluated using the GRADE approach. This study was registered in PROSPERO under protocol CRD42024597806.

RESULTS:

Six randomized controlled trials involving 2590 patients were included in the analysis. Of these, 1376 (53.13 %) received efsitora insulin. No significant differences were observed between efsitora and degludec in glycemic efficacy outcomes, including HbA1c reduction, fasting blood glucose, weight change, and proportion of patients achieving HbA1c <7 %. Regarding safety outcomes, most endpoints, such as adverse events, injection site reactions, hypersensitivity, severe hypoglycemia, and mortality, were comparable between groups, with no significant subgroup effects. However, subgroup analysis revealed a lower incidence of nocturnal hypoglycemia with efsitora in patients with type 2 diabetes, and a higher rate of serious adverse events in patients with type 1 diabetes, suggesting potential population-specific differences in safety profiles.

CONCLUSION:

Efsitora and degludec insulins show similar overall efficacy and safety in the management of diabetes. However, subgroup analyses indicate that patient-specific factors, such as diabetes type, may influence the risk of certain adverse events. These findings support the importance of individualized insulin selection based on patient characteristics and risk profiles.

2025-07-01·Endocrinology, diabetes & metabolism

Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis

Review

作者: Bhutto, Sadia Habib ; Bai, Nikeeta ; Dev, Shah ; Nancy, F. N. U. ; Abunada, Saaed ; Yusuf, Salih Abdella ; Khan, Areeba ; Umer, F. N. U. ; Bai, Sheela ; Manan, Abdul ; Zain ul Abiddin, Noshad ; Bai, Anusha ; Kumari, Usha ; Shevani, F. N. U.

ABSTRACT:

Introduction:

Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control. However, comprehensive comparisons with insulin degludec regarding continuous glucose monitoring (CGM) metrics and hypoglycaemia outcomes remain limited. This meta‐analysis evaluates these critical parameters.

Methods:

We conducted a systematic review and meta‐analysis of randomised controlled trials (RCTs) comparing once‐weekly BIF with once‐daily insulin degludec in type 1 and type 2 diabetes. Outcomes included CGM‐derived glycaemic variability, time in range, time above/below range and hypoglycaemia event rates. Data were pooled using random‐effects models, with heterogeneity assessed via I2 statistics.

Results:

Five RCTs (n = 2427) were included. BIF demonstrated comparable glycaemic variability (within‐day CV: MD = 0.06, p = 0.90; between‐day CV: MD = ‐0.26, p = 0.30) and Time in range (MD = 0.56, p = 0.27) versus degludec. However, BIF increased time spent in the mild hypoglycaemia range (54–69 mg/dL) (MD = 0.30, p = 0.0004) and clinically significant hypoglycaemia event rates (rate ratio = 1.20, p < 0.00001). Severe hypoglycaemia event rates were higher with BIF (rate ratio = 3.34, p < 0.0001). Nocturnal hypoglycaemia and time above range (> 250 mg/dL) did not differ significantly.

Conclusion:

Once‐weekly BIF provides similar overall glycaemic control to insulin degludec but with increased time in mild hypoglycaemia and higher event rates of clinically significant and severe hypoglycaemia. These findings highlight the need for individualised dosing and monitoring when transitioning to weekly insulin regimens.

2025-06-22·NEW ENGLAND JOURNAL OF MEDICINE

Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.

Article

作者: Connery, Lisa ; Bailey, Timothy ; Desouza, Cyrus ; Miller, Eden ; Carr, Molly C ; Rosenstock, Julio ; Child, Christopher J ; Knights, Alastair ; Leohr, Jennifer ; Wang, Qianqian

BACKGROUND:

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa (efsitora), a once-weekly basal insulin, may provide a benefit in adults with type 2 diabetes who have not received previous insulin therapy.

METHODS:

We conducted a 52-week, phase 3, open-label, treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin therapy. Participants were randomly assigned in a 1:1 ratio to receive once-weekly efsitora or once-daily insulin glargine U100 (glargine). Treatment with efsitora was initiated as a single dose of 100 U administered once weekly, with dose adjustments made every 4 weeks, as needed, at fixed doses of 150, 250, and 400 U to achieve fasting blood glucose levels of 80 to 130 mg per deciliter. Doses of glargine were adjusted weekly or more often according to a standard algorithm to reach the same glycemic goals. The primary end point, tested for noninferiority (noninferiority margin, 0.4 percentage points), was the change from baseline in the glycated hemoglobin level at 52 weeks.

RESULTS:

A total of 795 participants underwent randomization. The mean glycated hemoglobin level decreased from 8.20% at baseline to 7.05% at week 52 with efsitora (least-squares mean change, -1.19 percentage points) and from 8.28% to 7.08% with glargine (least-squares mean change, -1.16 percentage points); the estimated between-group difference of -0.03 percentage points (95% confidence interval [CI], -0.18 to 0.12) confirmed the noninferiority of efsitora to glargine. Superiority was not shown (P = 0.68). The rate of combined clinically significant hypoglycemia (glucose level, <54 mg per deciliter) or severe hypoglycemia (level 3; requiring assistance for treatment) was lower with efsitora than with glargine (0.50 events per participant-year of exposure with efsitora vs. 0.88 with glargine; estimated rate ratio, 0.57 [95% CI, 0.39 to 0.84]). At week 52, the mean total weekly insulin dose was 289.1 U per week with efsitora and 332.8 U per week with glargine (estimated between-group difference, -43.7 U per week; 95% CI, -62.4 to -25.0); the median number of dose adjustments needed was 2 with efsitora and 8 with glargine.

CONCLUSIONS:

In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora, administered in a fixed-dose regimen, was noninferior to once-daily glargine in reducing glycated hemoglobin levels. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT05662332.).

项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的新闻（医药）

2025-06-24

·医学新视点

一年少打约300针！NEJM、Lancet三连发：每周一次，长效胰岛素有效降糖

约三分之一的2型糖尿病患者在确诊后8年内需要胰岛素治疗。对低血糖的担忧和高频注射胰岛素带来的不便会让患者难以坚持按最佳剂量使用胰岛素。近年来，长效胰岛素的出现正在改变这样的挑战。Efsitora是一种每周一次皮下注射的基础胰岛素，它是一种融合蛋白，结合了新型单链胰岛素变体与人IgG2 Fc结构域。Efsitora与人胰岛素受体的结合亲和力比内源性胰岛素弱约两个数量级，这意味着这可以延长胰岛素活性，作用时间更长；同时，由于其具有较低的峰谷比，有望在整一周内帮助患者保持更稳定的血糖水平。QWINT系列研究评估了efsitora的安全性和有效性。此前发表的QWINT-2试验显示，在未接受过胰岛素治疗的2型糖尿病成人中，每周一次的efsitora治疗52周降低糖化血红蛋白（HbA1c）的效果不劣于每日一次的常用基础胰岛素；QWINT-5试验在1型糖尿病成人患者中证实了这一点。在第85届美国糖尿病协会（ADA）学术会议上，QWINT-1、QWINT-3和QWINT-4的积极结果公布，并分别同步发表于《新英格兰医学杂志》（NEJM）和《柳叶刀》（The Lancet）。这三项试验分别针对首次使用胰岛素、既往使用每日基础胰岛素、既往使用每日基础胰岛素和餐时胰岛素的2型糖尿病成年患者。在每项试验中，每周一次的efsitora在降低HbA1c方面均不劣于常用的每日基础胰岛素，且总体安全性相似。这三项研究的结果强化了efsitora通过每周给药简化胰岛素管理的潜力，意味着患者有望每年可减少近300次的胰岛素注射。QWINT-1试验：针对首次使用胰岛素患者截图来源：The New England journal of medicineQWINT-1试验是一项为期52周的开放标签、达标治疗3期试验，共795名既往未接受过胰岛素的2型糖尿病成年患者接受随机分组，按1:1接受每周一次的efsitora或每日一次的甘精胰岛素U100治疗。Efsitora采用固定剂量方案，初始剂量为每次100单位，此后每4周按需调整剂量，递增至每次150、250和400单位，以达到空腹血糖80~130 mg/dL的治疗目标。甘精胰岛素的剂量根据标准算法每周或更频繁地调整，以达到相同的血糖目标值。按治疗方案评估（无论患者依从性如何，或是否引入其他挽救治疗），efsitora组患者的平均HbA1c水平从基线时8.20%降至第52周时的7.05%，降低1.19%；而对照组患者从8.28%降至7.08%，降低1.16%；组间降幅差异为-0.03%（95%CI 0.18%~0.12%），落在非劣效性界值（0.4%）内，证实了efsitora不劣于对照胰岛素。在第52周时，efsitora组更多患者达到HbA1c水平＜7.0%（57% vs 52%）。与对照组相比，efsitora导致的低血糖事件减少了43%（RR 0.57，95%CI 0.39~0.84）：在52周时，临床显著低血糖事件（<54 mg/dL）或严重（3级）低血糖事件的估计发生率在efsitora组和对照组分别0.50次/患者-年和0.88次/患者-年。Efsitora组患者的胰岛素用量更低，平均胰岛素总剂量为289.1单位/周，而对照组为332.8单位/周，efsitora组剂量调整需求更少，中位数为2次，而对照组为8次。QWINT-3试验：针对已使用基础胰岛素治疗患者截图来源：The LancetQWINT-3是一项为期78周的开放标签、达标治疗3期临床试验，共有986名目前接受基础胰岛素治疗（不含餐时胰岛素）、最多接受三种非胰岛素降糖药物且血糖控制不佳（HbA1c水平在6.5%-10.0%之间）的2型糖尿病成年患者参与随机分组，按2:1接受每周一次efsitora（n=655）或每日一次德谷胰岛素（n=331）。根据患者基线时的空腹血糖浓度选择不同的起始剂量，每周评估并按需调整胰岛素剂量，直至第12周，之后每月调整一次，以达到目标空腹血糖浓度为80-120 mg/dL。所有患者均至少接受过一剂研究治疗，871名（88%）完成了78周的治疗。按治疗方案估计，从基线到第26周，efsitora组的平均HbA1c水平从7.80%下降至6.99%，降低0.81%；对照组患者从7.79%下降至7.08%，降低0.72%；组间降幅差异为-0.09%（95%CI 0.19~0.01），符合非劣效性界值（0.4%），表明efsitora不劣于对照胰岛素。此外，从基线到第52周，efsitora组的HbA1c水平降幅显著更大（降低0.78% vs 降低0.59%；p=0.0014）。两组患者从基线到第78周的HbA1c水平变化相似。从连续血糖监测结果来看，在第52周前的4周监测期间，efsitora组血糖患者的24hr内血糖达标时间更高，但两组患者在26周和78周时的数据相似。安全性方面，从基线到第78周，两组患者的2级低血糖或3级（严重）低血糖事件发生率相似（RR 1.14，95%CI 0.83~1.56；p=0.43），efsitora组为0.84次/患者-年，对照组为0.74次/患者-年。Efsitora组16%患者、对照组11%患者发生了严重不良事件，其中分别有7例（1%）和1例（＜1%）与治疗有关。试验期间有9人死亡（efsitora组7人，degludec组2人），但均与研究治疗无关。QWINT-4试验：针对已使用基础胰岛素和餐时胰岛素的患者截图来源：The LancetQWINT-4是一项为期26周的开放标签、达标治疗3期试验，共730名既往使用基础胰岛素和餐时胰岛素以及最多三种非胰岛素降糖药物治疗、且HbA1c水平为7.0%-10.0%的2型糖尿病患者按1:1随机分组接受efsitora（n=365）或每日一次甘精胰岛素（n=365）治疗。治疗期间，所有参与者均接受餐时赖脯胰岛素治疗。根据患者基线时的空腹血糖浓度选择不同的起始剂量，每周评估并按需调整胰岛素剂量，直至第12周，之后每月调整一次，以达到目标空腹血糖浓度为80-120 mg/dL。按治疗方案估计，从基线到第26周，efsitora组患者的平均HbA1c水平从8.18%下降至7.17%，降低1.01%；对照组患者从8.18%下降至7.18%，降低1.00%；组间降幅差异为-0.01%（95%CI -0.14~0.12），符合非劣效性界值（0.4%），表明efsitora不劣于对照胰岛素。在第26周前的4周连续血糖监测期间，两组患者在24hr内血糖达到、高于、低于目标区间的时间比例均没有显著差异。第26周时，efsitora组的每周胰岛素总剂量（592.9单位/周 vs 666.4单位/周）、每周基础胰岛素剂量（391.6单位/周 vs 426.6单位/周）和平均每日餐时胰岛素剂量（27.0单位/日 vs 34.6单位/日）都明显更低。治疗期间，两组患者的总体2级或3级低血糖发生率相似（6.6次/患者-年 vs 5.9次/患者-年；ERR 1.11，95%CI 0.85~1.44；p=0.44）；两组不良事件发生率相似，efsitora组7%和对照组6%的患者报告了严重不良事件。图片来源：123RF根据公开信息，礼来公司计划在今年年底前向全球监管机构提交efsitora用于治疗成人2型糖尿病的上市申请，期待这款长效胰岛素早日为患者带来更便捷的血糖管理选择。推荐阅读每周一次，减重20.4%；血糖达标率超70%！NEJM连发两篇，双靶点疗法带来多重获益新药每周一次，93%中国患者成功减重，还降三高、尿酸和脂肪肝！纪立农教授领衔研究登《柳叶刀》子刊每周一次，不仅降糖，还能减重、减少使用胰岛素！《柳叶刀》子刊：新药为2型糖尿病治疗提供新选择每周一次，强效降糖！《柳叶刀》子刊：新药包含两大明星药成分，低血糖风险更低NEJM：每周一次，82%患者至少减重5%！中国患者有望在今年用上新药欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。封面图来源：123RF参考资料（可上下滑动查看）[1] Julio Rosenstock, et al., (2025). Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. The N Engl J Med, DOI: 10.1056/NEJMoa2502796[2] Julie R. Ingelfinger, Clifford J. Rosen. (2025). Weekly Insulins and Therapeutic Burden in Type 2 Diabetes. The N Engl J Med, DOI: 10.1056/NEJMe2508147[3] Athena Philis-Tsimikas, et al., (2025). Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet, DOI: 10.1016/S0140-6736(25)01044-X[4] Thomas Blevins, et al., (2025). Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet, DOI: 10.1016/S0140-6736(25)01069-4 External Link[5] Edith Wing-Kar Chowa, Elaine Chowa. (2025). Future of once-weekly insulins in type 2 diabetes: efficacy and safety. Lancet: DOI: 10.1016/S0140-6736(25)01098-0[6] Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials. Retrieved June 24, 2025 from https://investor.lilly.com/news-releases/news-release-details/lillys-once-weekly-insulin-efsitora-alfa-demonstrated-a1c免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com分享，点赞，在看，传递医学新知

临床结果临床3期

2025-06-24

·求实药社

即将上市！礼来胰岛素周制剂3项III期研究结果公布

来源：医药魔方Info6月22日，礼来宣布了QWINT-1、QWINT-3和QWINT-4这3项III期研究的详细结果，这些研究评估了在成人2型糖尿病患者中胰岛素周制剂efsitora alfa（efsitora）的安全性和有效性。结果显示，efsitora在多项III期研究中显示出降低A1C的效果，且安全性与每日胰岛素一致。礼来计划在今年年底前向全球监管机构提交efsitora用于治疗成人2型糖尿病的上市申请。胰岛素efsitora是一种融合蛋白，结合了一种新型单链胰岛素变体和人IgG2 Fc结构域。它专为每周一次皮下给药而设计，凭借其低峰谷比，有望提供更稳定的血糖水平（减少血糖波动）。这3项研究的患者分别为首次使用胰岛素、之前使用过每日基础胰岛素以及之前同时使用过每日基础胰岛素联用餐时胰岛素治疗的患者。在每项试验中，每周一次的efsitora均达到了与每日基础胰岛素相比A1C降低非劣效的主要终点。这些研究的完整结果在2025年美国糖尿病协会（ADA）第85届科学会议上公布。同时，QWINT-1（一项首创的固定剂量研究）的结果发表于《新英格兰医学杂志》，而QWINT-3和QWINT-4的结果则发表于《柳叶刀》。在QWINT-1研究中，efsitora使A1C降低了1.31%，而甘精胰岛素降低了1.27%，在第52周达到疗效估计量。在该试验中，efsitora根据需要每四周调整至四个固定剂量，以控制血糖。在QWINT-3中，efsitora使A1C降低了0.86%，而德谷胰岛素降低了0.75%，在第26周达到疗效估计量。在QWINT-4中，efsitora使A1C降低了1.07%，与甘精胰岛素的1.07%相当，在第26周达到疗效估计量。在这两项试验中，efsitora采用传统胰岛素给药方式，根据每位患者的血糖水平进行调整。在上述三项试验中，efsitora显示出与两种最常用的每日基础胰岛素治疗2型糖尿病的安全性相当。在QWINT-1中，与甘精胰岛素相比，efsitora导致的低血糖事件减少了约40%，在52周内，两组的严重或具有临床意义的低血糖事件估计综合发生率分别为0.50 vs. 0.88（患者/年）。在QWINT-3中，在78周内时，德谷胰岛素相比，上述事件的发生率分别为0.84 vs. 0.74（患者/年）。在QWINT-4中，在26周内与甘精胰岛素相比，efsitora组的严重或具有临床意义低血糖事件估计综合发生率分别为6.6 vs. 5.9（患者/年）。礼来产品开发高级副总裁Jeff Emmick博士表示：“建立在礼来胰岛素治疗领域创新传统的基础上，每周一次的efsitora可能为需要胰岛素的2型糖尿病患者带来重大进步，每年减少300多次注射。这些结果强化了每周一次efsitora通过简化治疗方案减轻胰岛素治疗负担的潜力。我们期待与监管机构合作，将这一创新带给全球患者。”免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们国内唯一！多肽、代谢与减肥药领域顶尖盛会！PMO 2025展位火热预定中！扫码立即咨询电话：13816031174（同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

临床结果临床3期临床成功临床2期

2025-06-24

·PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

Eli Lilly has shared promising phase 3 results for its once-weekly insulin candidate efsitora alfa in adults with type 2 diabetes (T2D). All three studies met their primary endpoint of non-inferior A1C reduction compared to daily basal insulin, according to data presented at this year’s American Diabetes Association Scientific Sessions. More than 4.3 million people in the UK have diabetes, with T2D accounting for around 90% of all cases. Current treatment options focus on disease management and include diet and exercise, diabetes medications and insulin therapy. It is hoped that an insulin option specifically designed for once-weekly subcutaneous administration could improve adherence rates and quality of life for patients with the chronic condition. QWINT-1, which evaluated efsitora alfa in patients using insulin for the first time, showed that Lilly’s candidate reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52. In the trial, efsitora was titrated across four fixed doses at four-week intervals, as needed for blood glucose control. In QWINT-3 and QWINT-4, which enrolled patients who had previously used daily basal insulin, and those who had previously used daily basal insulin and mealtime insulin, respectively, efsitora was given using traditional insulin dosing, with adjustments based on each patient’s glucose level. At week 26 in QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec. At the same time point in QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine. Efsitora also demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for T2D across all three studies. Jeff Emmick, senior vice president of product development at Lilly, said: “These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach.” Lilly said it is planning to submit global regulatory applications for efsitora as a treatment for adults with T2D by the end of this year. “We look forward to working with regulatory agencies to bring this innovation to patients around the world,” Emmick said.

临床结果临床3期

100 项与 Basal Insulin Fc(Eli Lilly & Co.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床3期	美国	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	日本	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	阿根廷	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	波兰	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	斯洛伐克	Eli Lilly & Co.	2022-08-12
1型糖尿病	临床3期	中国台湾	Eli Lilly & Co.	2022-08-12
2型糖尿病	临床3期	美国	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	日本	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	阿根廷	Eli Lilly & Co.	2022-03-08
2型糖尿病	临床3期	匈牙利	Eli Lilly & Co.	2022-03-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05463744 (QWINT-5, CTgov)	临床3期	1型糖尿病	692	Insulin Efsitora Alfa (500 U/mL Insulin Efsitora Alfa)	鏇範壓衊願蓋廠夢鹽遞(鑰憲網夢夢願範壓廠觸) = 衊鹽憲餘齋襯壓顧齋醖廠獵蓋繭鹽齋醖範鏇餘 (齋顧網範艱願艱築膚鹹, 0.0469) 更多	-	2025-06-24
				Insulin Degludec (100 U/mL Insulin Degludec)	鏇範壓衊願蓋廠夢鹽遞(鑰憲網夢夢願範壓廠觸) = 積願積積夢餘繭廠製淵廠獵蓋繭鹽齋醖範鏇餘 (齋顧網範艱願艱築膚鹹, 0.0463) 更多
NCT05275400 (QWINT-3, CTgov)	临床3期	2型糖尿病	986	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora)	憲鬱齋憲廠襯鏇製構糧(遞築淵鑰糧襯蓋選鏇遞) = 膚鏇築壓獵齋遞觸鬱鏇積廠網糧製襯艱觸願獵 (積醖積範齋襯糧壓遞範, 0.0302) 更多	-	2025-06-03
				Insulin Degludec (100 U/mL - Insulin Degludec)	憲鬱齋憲廠襯鏇製構糧(遞築淵鑰糧襯蓋選鏇遞) = 製遞廠繭遞顧膚糧鹽顧積廠網糧製襯艱觸願獵 (積醖積範齋襯糧壓遞範, 0.0424) 更多
NCT05362058 (Qwint-2, CTgov)	临床3期	2型糖尿病	928	Insulin Efsitora Alfa (500 U/mL - Insulin Efsitora Alfa)	淵鏇夢遞蓋襯簾範鹽襯(鹹齋襯齋願窪製鹹糧獵) = 網網鑰襯淵夢蓋窪構齋積廠艱鏇蓋網襯鹽窪築 (鬱獵網鹽簾願蓋製醖繭, 0.0470) 更多	-	2025-05-16
				Insulin Degludec (100 U/mL - Insulin Degludec)	淵鏇夢遞蓋襯簾範鹽襯(鹹齋襯齋願窪製鹹糧獵) = 憲襯製鹹顧夢窪鹽廠蓋積廠艱鏇蓋網襯鹽窪築 (鬱獵網鹽簾願蓋製醖繭, 0.0473) 更多
NCT05462756 (QWINT-4, CTgov)	临床3期	2型糖尿病	730	Insulin Efsitora Alfa+Insulin Lispro (U100) (500 U/mL - Insulin Efsitora)	蓋膚顧構積繭襯積繭膚(醖遞鏇夢膚齋構憲觸夢) = 遞積窪簾鏇範醖壓衊襯襯襯繭淵衊範糧淵願蓋 (夢糧範憲淵憲糧範範蓋, 0.0463) 更多	-	2025-04-27
				Insulin Glargine+Insulin Lispro (U100) (100 U/mL - Insulin Glargine)	蓋膚顧構積繭襯積繭膚(醖遞鏇夢膚齋構憲觸夢) = 夢構鏇網窪艱鹹餘構醖襯襯繭淵衊範糧淵願蓋 (夢糧範憲淵憲糧範範蓋, 0.0463) 更多
NCT05463744 (QWINT-5, Company_Website) 人工标引	临床3期	1型糖尿病	692	Insulin efsitora alfa	鬱憲構膚顧鹹選製觸壓(鹹構夢鑰顧鏇壓範獵艱) = 獵鑰壓蓋積襯衊顧繭夢衊齋簾積繭鏇顧憲繭壓 (觸餘獵遞廠鹽鏇觸糧範 ) 达到更多	非劣	2024-09-10
				Insulin degludec	鬱憲構膚顧鹹選製觸壓(鹹構夢鑰顧鏇壓範獵艱) = 構獵蓋鏇顧鹽膚積壓製衊齋簾積繭鏇顧憲繭壓 (觸餘獵遞廠鹽鏇觸糧範 ) 达到更多
NCT05662332 (QWINT-1, NEWS) 人工标引	临床3期	2型糖尿病	-	Efsitora alfa	築艱窪獵顧築衊選鹽膚(憲艱艱遞壓夢壓鏇顧製) = 鬱鑰願憲構鏇醖網艱積餘淵繭鏇選壓顧簾遞窪 (淵鹹夢積鏇鏇衊鹹網窪 ) 达到更多	非劣	2024-09-09
				Insulin glargine	築艱窪獵顧築衊選鹽膚(憲艱艱遞壓夢壓鏇顧製) = 膚選積壓衊積壓鹽構餘餘淵繭鏇選壓顧簾遞窪 (淵鹹夢積鏇鏇衊鹹網窪 ) 达到更多
NCT05275400 (QWINT-3, NEWS \| PRNewswire) 人工标引	临床3期	2型糖尿病	-	Efsitora Alfa	糧選願範襯壓獵鬱構選(淵夢鑰襯築築壓衊觸淵) = 獵襯衊鑰築醖夢鹽窪蓋簾壓壓壓壓顧積顧蓋製 (艱範廠糧醖壓壓艱鑰構 ) 达到更多	非劣	2024-09-05
				Insulin degludec	糧選願範襯壓獵鬱構選(淵夢鑰襯築築壓衊觸淵) = 願夢繭鹽艱壓窪範積獵簾壓壓壓壓顧積顧蓋製 (艱範廠糧醖壓壓艱鑰構 ) 达到更多
NCT05462756 (QWINT-4, Biospace \| PRNewswire) 人工标引	临床3期	2型糖尿病	730	Efsitora	醖蓋窪壓鏇鹹鹹憲積選(簾鬱築淵鹽範鏇願糧構) = 選簾齋衊餘鑰鑰構積鑰齋鏇鏇願餘製鑰鹽簾壓 (艱廠廠壓鑰願構鹹繭顧 ) 更多	积极	2024-05-16
				Glargine	醖蓋窪壓鏇鹹鹹憲積選(簾鬱築淵鹽範鏇願糧構) = 憲衊糧憲積鑰淵鹽願鏇齋鏇鏇願餘製鑰鹽簾壓 (艱廠廠壓鑰願構鹹繭顧 ) 更多
NCT05362058 (Qwint-2, Biospace) 人工标引	临床3期	2型糖尿病	928	Efsitora alfa (Efsitora)	艱製鏇鏇鹽憲鑰艱憲齋(選憲淵壓糧繭積醖膚觸) = 齋糧製鬱鹹遞壓築繭簾衊鹽艱糧淵簾構願選鹽 (顧積觸製遞衊夢鹹鏇鹹 ) 达到更多	非劣	2024-05-16
				Degludec (Tresiba)	艱製鏇鏇鹽憲鑰艱憲齋(選憲淵壓糧繭積醖膚觸) = 遞壓網膚壓膚鹽膚壓獵衊鹽艱糧淵簾構願選鹽 (顧積觸製遞衊夢鹹鏇鹹 ) 达到更多
NCT04450394 \| NCT03736785 \| NCT04450407 (phase 2, EASD2023)	临床2期	-	912	Once-weekly insulin efsitora alfa	願艱糧構廠鑰選襯鏇蓋(鬱衊網觸齋遞醖積顧衊) = 衊衊積製蓋觸顧築築築廠艱窪艱鑰簾顧顧鏇製 (壓鬱壓壓夢襯願築範積 ) 更多	积极	2023-10-03
				Once daily degludec	願艱糧構廠鑰選襯鏇蓋(鬱衊網觸齋遞醖積顧衊) = 醖獵鑰鏇繭衊鹽淵網鹹廠艱窪艱鑰簾顧顧鏇製 (壓鬱壓壓夢襯願築範積 ) 更多